Oxcarbazepine

Mood Stabilizer, Anticonvulsant

Oxcarbazepine

Trileptal

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions2 edges

Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines

Variant:hla-b 1502 pos contraindication CPIC A 90 / 100Rate

CPIC rec 8094683 [Strong]: If patient is oxcarbazepine-naïve, do not use oxcarbazepine. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 29392710]

Variant:hla-b 1502 pos risk hypersensitivity CPIC A 20 / 100Rate

CPIC rec 8094685 [Optional]: The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 29392710]

Patient experience

No patient-experience reports yet.

+ Add an interaction

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary

Classes

Mood Stabilizer, Anticonvulsant

Pharmacy

Pharmacology

Purported mechanism

Sodium channel blocker